Chronic Inflammatory Demyelinating Polyneuropathy

Hizentra® in Inflammatory Neuropathies - pHeNIx Study
NCT04672733 | PHASE 3 | OBSERVATIONAL

The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).

Trial Information
27 Sites
100 Participants
Recruiting
18 Years to 7 Years

If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
CHU Amiens Picardie
Amiens,France,80054
CHU Angers
Angers,France
Hpital priv de La Casamance
Aubagne,France
CH Bayonne
Bayonne,France
Hpital Pellegrin
Bordeaux,France
CHRU Brest
Brest,France
Hpital Henri Mondor
Créteil,France
Hpital Bictre
Le Kremlin-Bicêtre,France
CH Libourne
Libourne,France
Hpital Roger Salengro, CHU Lille
Lille,France
Hpital Dupuytren
Limoges,France
Hpital Pierre Wertheimer,HCL
Lyon,France
Hpital de la Timone
Marseille,France
CHU Montpellier
Montpellier,France
CHRU Nancy
Nancy,France
CHU Nantes
Nantes,France
Hpital Pasteur
Nice,France
Hpital Lariboisire
Paris,France
La PitiSalptrire
Paris,France
CHU Poitiers
Poitiers,France,86000
Centre hospitalier priv Saint Grgoire
Rennes,France,35760
Hpital Charles Nicolle
Rouen,France
CHU SaintEtienne
Saint-Étienne,France
CHU de Strasbourg
Strasbourg,France,67091
CHU Toulouse
Toulouse,France
CHR Tours
Tours,France
CH de Valence
Valence,France,26000

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov